Immunotherapy for Ovarian Cancer: Disappointing or Promising?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunotherapy for Ovarian Cancer: Disappointing or Promising?

Published:2024-01-17 Issue: Volume: Page:
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Deng Mengqi¹,Tang Fan¹,Chang Xiangyu¹,Liu Penglin¹,Ji Xuechao¹,Hao Menglin¹,Wang Yixiao¹,Yang Ruiye¹,Ma Qingqing¹²,Zhang Yubo¹³,Miao Jinwei¹^ORCID

Affiliation:

1. Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100006, China

2. Nanyuan Hospital of Fengtai District, Beijing 100006, China

3. Qingdao Hospital, University of Health and Rehabilitation Sciences, Shandong 266011, China

Funder

Beijing Hospital Authority

Gynecological Tumor Precise Diagnosis and Treatment Innovation Studio

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c00986

Reference115 articles.

1. Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study

2. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity

3. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer

4. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP